SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?


To: Biotech Jim who wrote (1891)4/5/2016 10:38:30 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 3559
 
Boost in efficacy by PBD (from the bi-specific perspective) definitely would be welcomed by oncologist. PBD bind nicely to certain DNA sequence (where chemically induce break-down), so maybe they did saw opportunity there??? Anyway, in last few investor presentations management promoted their efforts with bi-specific....so...regular interval view of their patent applications may pinpoint what they have in mind!